FDA Generics Office Hopes To Clear Unmeasured ANDAs
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA’s Office of Generic Drugs restructures again and adds specialist who helped relieve supplement backlog to improve ANDA review process.